BACKGROUND: Angiotensin II (Ang II) plays an important role in cardiovascular disease. It also leads to the activation of coagulation. The coagulation protease thrombin induces cellular responses by activating protease-activated receptor 1 (PAR-1). We investigated whether PAR-1 contributes to Ang II-induced cardiovascular remodeling and inflammation. METHODS AND RESULTS: PAR-1+/+ (wild-type; WT) and PAR-1-/- mice were infused with Ang II (600 ng/kg/min) for up to 4 weeks. In WT mice, this dose of Ang II did not cause a significant increase in blood pressure but it did cause pathological changes in both the aorta and the heart. Ang II infusion resulted in vascular remodeling of the aorta, demonstrated by a significant increase in medial wall thickening and perivascular fibrosis. Importantly, both parameters were significantly attenuated by PAR-1 deficiency. Furthermore, perivascular fibrosis around coronary vessels was reduced in Ang II-treated PAR-1-/- mice compared to WT mice. In addition, PAR-1 deficiency significantly attenuated Ang II induction of inflammatory cytokines and profibrotic genes in the aortas compared to WT mice. Finally, PAR-1 deficiency had no effect on Ang II-induced heart hypertrophy. However, the heart function measured by fractional shortening was less impaired in PAR-1-/- mice than in WT mice. CONCLUSION: Our data indicate that PAR-1 plays a significant role in cardiovascular remodeling mediated by a blood pressure-independent action of Ang II.
BACKGROUND:Angiotensin II (Ang II) plays an important role in cardiovascular disease. It also leads to the activation of coagulation. The coagulation protease thrombin induces cellular responses by activating protease-activated receptor 1 (PAR-1). We investigated whether PAR-1 contributes to Ang II-induced cardiovascular remodeling and inflammation. METHODS AND RESULTS:PAR-1+/+ (wild-type; WT) and PAR-1-/- mice were infused with Ang II (600 ng/kg/min) for up to 4 weeks. In WT mice, this dose of Ang II did not cause a significant increase in blood pressure but it did cause pathological changes in both the aorta and the heart. Ang II infusion resulted in vascular remodeling of the aorta, demonstrated by a significant increase in medial wall thickening and perivascular fibrosis. Importantly, both parameters were significantly attenuated by PAR-1 deficiency. Furthermore, perivascular fibrosis around coronary vessels was reduced in Ang II-treated PAR-1-/- mice compared to WT mice. In addition, PAR-1deficiency significantly attenuatedAng II induction of inflammatory cytokines and profibrotic genes in the aortas compared to WT mice. Finally, PAR-1 deficiency had no effect on Ang II-induced heart hypertrophy. However, the heart function measured by fractional shortening was less impaired in PAR-1-/- mice than in WT mice. CONCLUSION: Our data indicate that PAR-1 plays a significant role in cardiovascular remodeling mediated by a blood pressure-independent action of Ang II.
Authors: P Andrade-Gordon; C K Derian; B E Maryanoff; H C Zhang; M F Addo; B P Damiano; M R D'Andrea; A L Darrow; L de Garavilla; A J Eckardt; E C Giardino; B J Haertlein; D F McComsey Journal: J Pharmacol Exp Ther Date: 2001-07 Impact factor: 4.030
Authors: D N Müller; E M Mervaala; R Dechend; A Fiebeler; J K Park; F Schmidt; J Theuer; V Breu; N Mackman; T Luther; W Schneider; D Gulba; D Ganten; H Haller; F C Luft Journal: Am J Pathol Date: 2000-07 Impact factor: 4.307
Authors: Richard Müller-Brunotte; Thomas Kahan; Begoña López; Magnus Edner; Arantxa González; Javier Díez; Karin Malmqvist Journal: J Hypertens Date: 2007-09 Impact factor: 4.844
Authors: Vitantonio Di Bello; Enrica Talini; Giulia Dell'Omo; Cristina Giannini; Maria Grazia Delle Donne; Maria Laura Canale; Carmela Nardi; Caterina Palagi; Frank Lloyd Dini; Giuseppe Penno; Stefano Del Prato; Mario Marzilli; Roberto Pedrinelli Journal: Am J Hypertens Date: 2009-12-31 Impact factor: 2.689
Authors: H Laine; O T Raitakari; H Niinikoski; O P Pitkänen; H Iida; J Viikari; P Nuutila; J Knuuti Journal: J Am Coll Cardiol Date: 1998-07 Impact factor: 24.094
Authors: Tomasz P Mikolajczyk; Ryszard Nosalski; Piotr Szczepaniak; Klaudia Budzyn; Grzegorz Osmenda; Dominik Skiba; Agnieszka Sagan; Jing Wu; Antony Vinh; Paul J Marvar; Bartlomiej Guzik; Jakub Podolec; Grant Drummond; Heinrich E Lob; David G Harrison; Tomasz J Guzik Journal: FASEB J Date: 2016-02-12 Impact factor: 5.191
Authors: Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos Journal: Arterioscler Thromb Vasc Biol Date: 2018-04-05 Impact factor: 8.311
Authors: Ching-Hui Sia; Sock-Hwee Tan; Siew-Pang Chan; Stephanie Marchesseau; Hui-Wen Sim; Leonardo Carvalho; Ruth Chen; Nor Hanim Mohd Amin; Alan Yean-Yip Fong; Arthur Mark Richards; Christina Yip; Mark Y Chan Journal: Pharmaceuticals (Basel) Date: 2022-06-06
Authors: Alexander A Boucher; Leah Rosenfeldt; Duaa Mureb; Jessica Shafer; Bal Krishan Sharma; Adam Lane; Rebecca R Crowther; Melanie C McKell; Jordan Whitt; Theresa Alenghat; Joseph Qualls; Silvio Antoniak; Nigel Mackman; Matthew J Flick; Kris A Steinbrecher; Joseph S Palumbo Journal: J Thromb Haemost Date: 2019-10-11 Impact factor: 5.824
Authors: Michael F Bode; Clare M Schmedes; Grant J Egnatz; Vanthana Bharathi; Yohei M Hisada; David Martinez; Tomohiro Kawano; Alice Weithauser; Leah Rosenfeldt; Ursula Rauch; Joseph S Palumbo; Silvio Antoniak; Nigel Mackman Journal: Sci Rep Date: 2021-07-12 Impact factor: 4.996